Working... Menu

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02953314
Recruitment Status : Completed
First Posted : November 2, 2016
Last Update Posted : October 5, 2018
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : August 2018
  Actual Study Completion Date : August 2018